ALIGOS THERAPEUTICS INC. - COMMON STOCK

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results

07 May 2024 15:05:00 By Nasdaq GlobeNewswire

Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024

30 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study

25 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD

25 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024

09 Apr 2024 07:00:01 By Nasdaq GlobeNewswire

Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

03 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies

27 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

18 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

12 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024

05 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024

26 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024

20 Feb 2024 07:00:01 By Nasdaq GlobeNewswire

Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments

13 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)

07 Dec 2023 15:05:00 By Nasdaq GlobeNewswire

Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference

20 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile

13 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)

10 Nov 2023 07:05:00 By Nasdaq GlobeNewswire

Aligos Therapeutics to Present Multiple Posters at AASLD’s The Liver Meeting® 2023, Highlighting Progress for Its Clinical Stage Portfolio, including Lead THR-β Agonist for the Treatment of NASH, ALG-055009; ALG-000184, the Company’s Lead CAM-E Molecule, and Updates on Several Preclinical Candidates for the Treatment of Chronic Hepatitis B, in Addition to the Recently Announced Late Breaker Poster (#5028-C)

07 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data

03 Nov 2023 15:30:00 By Nasdaq GlobeNewswire

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results

02 Nov 2023 15:05:00 By Nasdaq GlobeNewswire